AGAP2 and nonpapillary renal cell carcinoma: It has been observed to be more active in tumor tissues and is associated with OS.[80] LINC00894 potentially modulates the advancement of cancer, spread to other parts of the body, and resistance to drugs through ceRNA-associated processes in ccRCC.[60] The lncRNA AGAP2-AS1, produced by MSCs, enhances the characteristics of stemness and resistance to trastuzumab in breast cancer by controlling the expression of CPT1 and the oxidation of FA.[81]